Literature DB >> 15488453

Lack of evidence for use of glatiramer acetate in multiple sclerosis.

Luca M Munari1, Graziella Filippini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15488453     DOI： 10.1016/S1474-4422(04)00899-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  4 in total

1.  Interferon as a treatment for uveitis associated with multiple sclerosis.

Authors:  M D Becker; A Heiligenhaus; T Hudde; B Storch-Hagenlocher; B Wildemann; T Barisani-Asenbauer; C Thimm; N Stübiger; M Trieschmann; C Fiehn
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

2.  Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.

Authors:  Olaf Stüve; Sawsan Youssef; Martin S Weber; Stefan Nessler; Hans-Christian von Büdingen; Bernhard Hemmer; Thomas Prod'homme; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

3.  Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

Authors:  Narender Nath; Musfiquidin Khan; Ramandeep Rattan; Ashutosh Mangalam; Randhir S Makkar; Carloe de Meester; Luc Bertrand; Inderjit Singh; Yingjie Chen; Benoit Viollet; Shailendra Giri
Journal:  Biochem Biophys Res Commun       Date:  2009-05-30       Impact factor: 3.575

Review 4.  Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities.

Authors:  Rhoanne C McPherson; Stephen M Anderton
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-09       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.